These results suggest that genetic or environmental factors that modify CFTR function may modulate the onset and severity of airway mucus obstruction and that CFTR may serve as a potential therapeutic target in patients with COPD. This evidence concerns the gene CFTR and chronic obstructive pulmonary disease.